A more equitable health system

Health and disability
Written By Clare Maxwell

Summary

Equity Economics worked with The McKell Institute to deliver a report that explores the role complimentary medicines could play in achieving greater equity in the Australian healthcare system.

Through the targeted provision of clinically tested complimentary medicines for certain patients, such as vitamins for pregnant women, better health outcomes can be achieved that have the potential to reduce healthcare costs in the long run.

The report combines cost benefit analysis and costings of certain complimentary medicines where there is a strong, clinical evidence base of effectiveness.

The report received television coverage on Seven News and has been widely referred to in related industries.  

Read the full report

Similar Reports

Featured
Inclusion is the Future: Opportunities for Enhanced Bilateral Trade and Investment between Indonesia and Australia in Medical Devices and Assistive Technology
Inclusion is the Future: Opportunities for Enhanced Bilateral Trade and Investment between Indonesia and Australia in Medical Devices and Assistive Technology

Equity Economics worked with Katalis to produce this market insight which digs deep into the nuances of Indonesia’s booming fintech industry and how it can forge a connection with its neighbour Australia.

Measuring the Gap in Health Expenditure: Aboriginal and Torres Strait Islander Australians
Measuring the Gap in Health Expenditure: Aboriginal and Torres Strait Islander Australians

Equity Economics, in partnership with the National Aboriginal Community Controlled Health Organisation (NACCHO), undertook an analysis of the gap in health expenditure for Aboriginal and Torres Strait Islander people. In order to calculate the gap, we accounted for the burden of disease, which is more than twice the rate for the Aboriginal and Torres Strait Islander population than for the non-Indigenous population.

Towards a strengthened rare disease workforce for Australia
Towards a strengthened rare disease workforce for Australia

Australia’s first nationally coordinated effort to address rare diseases—the National Strategic Action Plan for Rare Diseases —called for the development of a national rare disease workforce strategy that responds to current and future demands, including the impact of genomics. This White Paper is an initial step to progress that priority.

Clare Maxwell
Previous

Easing rising disadvantage
Next

Inclusive prosperity report: Australia’s record & the road ahead